Best Holdings, which operates five-star hotel Le Méridien Dhaka, registered a 32 percent year-on-year growth in profit in the July-March period of the current fiscal year of 2023-24, attributing it to an increase in occupancy.
The prime index of the DSE decreased 0.6% before closing the day at 5,690.78
The DSEX fell 1.74 points to 5,725.28
It hit Tk 1,095 crore, up by 34% from the previous day
Stocks in Bangladesh yesterday maintained their gaining streak to four days consecutively riding on investors’ increased interest in shares of food and allied, pharmaceutical, financial and telecommunication companies.
Beximco Pharmaceuticals’ profits in the January-March period of fiscal year (FY) 2023-24 grew by 51 percent from that in the same period of the previous fiscal year, owing to higher sales and efficient cost management.
IBN Sina Pharmaceutical Industry secured a 44 percent year-on-year rise in profit in the January-March period of fiscal year 2023-24, which it attributed to an aggressive marketing strategy and proactive support from the management.
It lost 1.45% to close at 5,778.76 points
There were also positive changes in the market capitalisation of food and allied, engineering, and telecommunication scrips, it said.
Best Holdings, which operates five-star hotel Le Méridien Dhaka, registered a 32 percent year-on-year growth in profit in the July-March period of the current fiscal year of 2023-24, attributing it to an increase in occupancy.
The prime index of the DSE decreased 0.6% before closing the day at 5,690.78
The DSEX fell 1.74 points to 5,725.28
It hit Tk 1,095 crore, up by 34% from the previous day
Stocks in Bangladesh yesterday maintained their gaining streak to four days consecutively riding on investors’ increased interest in shares of food and allied, pharmaceutical, financial and telecommunication companies.
Beximco Pharmaceuticals’ profits in the January-March period of fiscal year (FY) 2023-24 grew by 51 percent from that in the same period of the previous fiscal year, owing to higher sales and efficient cost management.
IBN Sina Pharmaceutical Industry secured a 44 percent year-on-year rise in profit in the January-March period of fiscal year 2023-24, which it attributed to an aggressive marketing strategy and proactive support from the management.
It lost 1.45% to close at 5,778.76 points
There were also positive changes in the market capitalisation of food and allied, engineering, and telecommunication scrips, it said.
In its daily market update, Shanta Securities said the market movement was driven by negative changes in the market capitalisation of travel and leisure, paper and printing, and bank scrips.